Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

CDKN1A-mediated responsiveness of MLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitors.

Chen YP, Lin HJ, Chen JS, Tsai MY, Hsieh HP, Chang JY, Chen NF, Chang KC, Huang WT, Su WC, Yang ST, Chang WC, Hung LY, Chen TY.

Int J Cancer. 2014 Aug 1;135(3):751-62. doi: 10.1002/ijc.28708. Epub 2014 Jan 13.

2.

Leukemic fusion genes MLL/AF4 and AML1/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT.

Gessner A, Thomas M, Castro PG, Büchler L, Scholz A, Brümmendorf TH, Soria NM, Vormoor J, Greil J, Heidenreich O.

Leukemia. 2010 Oct;24(10):1751-9. doi: 10.1038/leu.2010.155. Epub 2010 Aug 5.

PMID:
20686504
3.

AAV8 vector expressing IL24 efficiently suppresses tumor growth mediated by specific mechanisms in MLL/AF4-positive ALL model mice.

Tamai H, Miyake K, Yamaguchi H, Takatori M, Dan K, Inokuchi K, Shimada T.

Blood. 2012 Jan 5;119(1):64-71. doi: 10.1182/blood-2011-05-354050. Epub 2011 Oct 24.

4.

Methylation-mediated repression of microRNA-143 enhances MLL-AF4 oncogene expression.

Dou L, Zheng D, Li J, Li Y, Gao L, Wang L, Yu L.

Oncogene. 2012 Jan 26;31(4):507-17. doi: 10.1038/onc.2011.248. Epub 2011 Jun 27.

PMID:
21706045
5.

Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target.

Hartsink-Segers SA, Zwaan CM, Exalto C, Luijendijk MW, Calvert VS, Petricoin EF, Evans WE, Reinhardt D, de Haas V, Hedtjärn M, Hansen BR, Koch T, Caron HN, Pieters R, Den Boer ML.

Leukemia. 2013 Mar;27(3):560-8. doi: 10.1038/leu.2012.256. Epub 2012 Sep 3.

6.
7.

t(4;11) leukemias display addiction to MLL-AF4 but not to AF4-MLL.

Kumar AR, Yao Q, Li Q, Sam TA, Kersey JH.

Leuk Res. 2011 Mar;35(3):305-9. doi: 10.1016/j.leukres.2010.08.011. Epub 2010 Sep 25.

8.

Simultaneous inhibition of DNA methyltransferase and histone deacetylase induces p53-independent apoptosis via down-regulation of Mcl-1 in acute myelogenous leukemia cells.

Nishioka C, Ikezoe T, Yang J, Udaka K, Yokoyama A.

Leuk Res. 2011 Jul;35(7):932-9. doi: 10.1016/j.leukres.2011.04.004. Epub 2011 May 7.

PMID:
21550660
9.

HoxA9 induces insulin-like growth factor-1 receptor expression in B-lineage acute lymphoblastic leukemia.

Whelan JT, Ludwig DL, Bertrand FE.

Leukemia. 2008 Jun;22(6):1161-9. doi: 10.1038/leu.2008.57. Epub 2008 Mar 13.

PMID:
18337761
10.

Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4.

Liu H, Westergard TD, Cashen A, Piwnica-Worms DR, Kunkle L, Vij R, Pham CG, DiPersio J, Cheng EH, Hsieh JJ.

Cancer Cell. 2014 Apr 14;25(4):530-42. doi: 10.1016/j.ccr.2014.03.008.

11.

MicroRNA-142-3p inhibits cell proliferation in human acute lymphoblastic leukemia by targeting the MLL-AF4 oncogene.

Dou L, Li J, Zheng D, Li Y, Gao X, Xu C, Gao L, Wang L, Yu L.

Mol Biol Rep. 2013 Dec;40(12):6811-9. doi: 10.1007/s11033-013-2798-6. Epub 2013 Sep 22.

PMID:
24057258
12.

The MLL fusion gene, MLL-AF4, regulates cyclin-dependent kinase inhibitor CDKN1B (p27kip1) expression.

Xia ZB, Popovic R, Chen J, Theisler C, Stuart T, Santillan DA, Erfurth F, Diaz MO, Zeleznik-Le NJ.

Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14028-33. Epub 2005 Sep 16.

13.

MLL fusion-driven activation of CDK6 potentiates proliferation in MLL-rearranged infant ALL.

van der Linden MH, Willekes M, van Roon E, Seslija L, Schneider P, Pieters R, Stam RW.

Cell Cycle. 2014;13(5):834-44. doi: 10.4161/cc.27757.

14.

Combined effects of the two reciprocal t(4;11) fusion proteins MLL.AF4 and AF4.MLL confer resistance to apoptosis, cell cycling capacity and growth transformation.

Gaussmann A, Wenger T, Eberle I, Bursen A, Bracharz S, Herr I, Dingermann T, Marschalek R.

Oncogene. 2007 May 17;26(23):3352-63. Epub 2006 Nov 27.

PMID:
17130830
15.

Targeting MLL-AF4 with short interfering RNAs inhibits clonogenicity and engraftment of t(4;11)-positive human leukemic cells.

Thomas M, Gessner A, Vornlocher HP, Hadwiger P, Greil J, Heidenreich O.

Blood. 2005 Nov 15;106(10):3559-66. Epub 2005 Jul 26.

16.

AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53.

Kalous O, Conklin D, Desai AJ, Dering J, Goldstein J, Ginther C, Anderson L, Lu M, Kolarova T, Eckardt MA, Langerød A, Børresen-Dale AL, Slamon DJ, Finn RS.

Breast Cancer Res Treat. 2013 Oct;141(3):397-408. doi: 10.1007/s10549-013-2702-z. Epub 2013 Oct 5.

PMID:
24091768
17.

AF4 and AF4-MLL mediate transcriptional elongation of 5-lipoxygenase mRNA by 1, 25-dihydroxyvitamin D3.

Ahmad K, Scholz B, Capelo R, Schweighöfer I, Kahnt AS, Marschalek R, Steinhilber D.

Oncotarget. 2015 Sep 22;6(28):25784-800. doi: 10.18632/oncotarget.4703.

18.

Expression of MLL-AF4 or AF4-MLL fusions does not impact the efficiency of DNA damage repair.

Castaño J, Herrero AB, Bursen A, González F, Marschalek R, Gutiérrez NC, Menendez P.

Oncotarget. 2016 May 24;7(21):30440-52. doi: 10.18632/oncotarget.8938.

19.
20.

FLT3 activation cooperates with MLL-AF4 fusion protein to abrogate the hematopoietic specification of human ESCs.

Bueno C, Ayllón V, Montes R, Navarro-Montero O, Ramos-Mejia V, Real PJ, Romero-Moya D, Araúzo-Bravo MJ, Menendez P.

Blood. 2013 May 9;121(19):3867-78, S1-3. doi: 10.1182/blood-2012-11-470146. Epub 2013 Mar 11.

Supplemental Content

Support Center